PARP activation is a characteristic of several pathological conditions and diseases in addition to cancer, and as such, there is considerable interest in evaluating PARP inhibitors for the treatment of diabetic retinopathy, cardiovascular disease, inflammation, and stroke [6], [15]. This evidence concerns the gene PARP1 and diabetic retinopathy.